How India Exports Azathioprine to the World

In the United States, azathioprine is approved for various indications, including the prevention of organ rejection in kidney transplant recipients and the treatment of rheumatoid arthritis. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for azathioprine tablets, indicating a competitive generic market. Notably, the brand-name drug Imuran (azathioprine) received FDA approval prior to January 1, 1982, with generic versions subsequently entering the market. The presence of numerous ANDA approvals underscores the robust demand and established regulatory pathway for azathioprine in the U.S. market.

Given that 53.7% of India's azathioprine exports are destined for the United States, Indian exporters must adhere to stringent FDA regulations, including compliance with Current Good Manufacturing Practices (cGMP) and successful ANDA submissions. The substantial number of active Indian exporters (134) reflects the competitive landscape and the importance of maintaining high regulatory standards to ensure market access.

In the European Union, azathioprine is subject to the European Medicines Agency's (EMA) centralized or decentralized marketing authorization procedures, depending on the specific application. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of azathioprine within the United Kingdom. Both regulatory bodies require compliance with the European Union's Good Manufacturing Practice (EU GMP) guidelines, ensuring the quality and safety of medicinal products.

With Germany, the United Kingdom, and France collectively accounting for approximately 23% of India's azathioprine exports, Indian manufacturers must ensure adherence to EU and UK regulatory requirements. This includes obtaining the necessary marketing authorizations and demonstrating compliance with GMP standards to facilitate market entry and sustain export volumes.

Azathioprine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global healthcare. The 2025 edition of the WHO Model List, published in September 2025, features azathioprine among the essential medicines recommended for priority health needs. This inclusion highlights the drug's critical role in treating conditions such as autoimmune diseases and in organ transplantation protocols.

In terms of pharmacopoeial standards, azathioprine is monographed in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, efficacy, and safety of azathioprine formulations, facilitating international trade and acceptance.

In India, azathioprine is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. This classification mandates that azathioprine can only be sold by retail on the prescription of a registered medical practitioner. Additionally, the Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of the latest notification in March 2025, azathioprine is subject to a ceiling price, ensuring its affordability and accessibility within the Indian market.

For export purposes, Indian manufacturers are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT). This certificate is essential for the export of pharmaceutical products and ensures compliance with national and international regulatory standards.

Azathioprine's primary patents have long expired, leading to a competitive generic market globally. The absence of active patents allows multiple manufacturers to produce and export azathioprine, contributing to its widespread availability and affordability. This competitive landscape is evident in the substantial number of active Indian exporters (134) and the diverse range of destination countries (68) for azathioprine exports.

In June 2025, the NPPA revised the ceiling price for azathioprine tablets, reducing it by 5% to enhance affordability for patients. This adjustment reflects the Indian government's commitment to making essential medicines more accessible.

In September 2025, the WHO updated its Model List of Essential Medicines, reaffirming azathioprine's inclusion. This update underscores the drug's continued importance in global healthcare and may influence procurement policies in various countries.

In November 2025, the EMA issued a new guideline on the quality requirements for azathioprine-containing products, emphasizing the need for stringent impurity control. This guideline aims to ensure the safety and efficacy of azathioprine formulations within the European market.

In January 2026, the FDA approved a new generic version of azathioprine tablets, further increasing competition in the U.S. market. This approval is expected to contribute to lower prices and improved patient access to azathioprine.

In February 2026, the CDSCO implemented a new requirement for azathioprine manufacturers to submit periodic safety update reports (PSURs) to monitor the drug's safety profile. This regulatory change aims to enhance pharmacovigilance and ensure patient safety.

These developments highlight the dynamic regulatory environment surrounding azathioprine and the ongoing efforts to ensure its quality, safety, and accessibility in both domestic and international markets.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs), with approximately 60–70% of these essential raw materials imported from China. This dependency poses a significant risk, as any disruption in Chinese supply chains can directly affect India's ability to produce Active Pharmaceutical Ingredients (APIs) like Azathioprine. For instance, in September 2025, China reduced the prices of 41 APIs and KSMs by 40–50%, aiming to undercut Indian manufacturers and potentially destabilize the domestic API industry.

Furthermore, the closure of the Strait of Hormuz in March 2026 due to escalating conflicts has disrupted the supply of naphtha, a crucial feedstock for chemical production. This disruption has led to force majeure declarations and production cutbacks in Asia's chemical industry, indirectly affecting the availability of raw materials necessary for API manufacturing.

The export market for Azathioprine is highly concentrated, with the top five Indian exporters—RPG Life Sciences Limited, Zydus Lifesciences Limited, Amneal Pharmaceuticals Private Limited, Cadila Healthcare Limited, and Granules India Limited—accounting for 93.2% of total exports. RPG Life Sciences Limited alone holds a 35.8% share. This concentration increases the risk of supply disruptions, as issues affecting any of these key suppliers could significantly impact global availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to reduce dependency on imports by boosting domestic production of critical APIs and KSMs. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a significant step toward self-reliance.

Geopolitical tensions have led to significant disruptions in global shipping routes. The closure of the Strait of Hormuz in March 2026 has halted oil tanker movements and disrupted the supply of raw materials essential for pharmaceutical manufacturing. Additionally, instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa's Cape of Good Hope, adding delays and increasing transportation costs.

These disruptions have cascading effects on the pharmaceutical supply chain, leading to potential shortages and increased prices for drugs like Azathioprine. The FDA actively monitors such situations to prevent and mitigate shortages of FDA-regulated products.

• Diversify Raw Material Sources: Reduce dependency on Chinese KSMs by sourcing from multiple countries or developing domestic production capabilities.

• Strengthen Domestic Manufacturing: Leverage government initiatives like the PLI scheme to enhance local API and KSM production, reducing reliance on imports.

• Expand Supplier Base: Encourage the entry of new manufacturers into the Azathioprine market to decrease supplier concentration and mitigate single-source risks.

• Enhance Supply Chain Monitoring: Implement robust systems to monitor geopolitical developments and shipping disruptions, allowing for proactive adjustments to supply chain strategies.

• Develop Contingency Plans: Establish alternative logistics routes and maintain strategic reserves of critical raw materials to buffer against supply chain disruptions.

RISK_LEVEL: HIGH